Alendronate treatment in children with osteogenesis imperfecta.

Simple item page
dc.contributor.authorAkcay, Teomanen_US
dc.contributor.authorTuran, Serapen_US
dc.contributor.authorGuran, Tulayen_US
dc.contributor.authorBereket, Abdullahen_US
dc.date.accessioned2008-02-04en_US
dc.date.accessioned2009-05-27T05:09:43Z
dc.date.available2008-02-04en_US
dc.date.available2009-05-27T05:09:43Z
dc.date.issued2008-02-04en_US
dc.description.abstractBACKGROUND: Recent studies reported beneficial effect of cyclical intravenous administration of pamidronate in children and adolescents with osteogenesis imperfecta (OI). However, this treatment requires frequent hospital admissions and is relatively expensive. Alendronate is an oral bisphosphonate effectively used in adults with osteoporosis. Experience with alendronate treatment in children with OI is limited. AIMS: To report our experience with alendronate in children with OI. METHODS: 12 children with OI (7 with type I, 4 with type III and 1 with type IV; 7 boys, 5 girls) aged 1.8 to 15.4 years (7.9+/-; 4.4 yrs) were included in this retrospective study. The patients were treated with alendronate in a dose of 5-10 mg/day along with calcium (500 mg/day) and vitamin D (400-1000 IU/day) supplements for 19.8+/-11.3 months (range: 7-46 months). Serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), osteocalcin (OC), pyrilinks-D and urinary Ca/Cr ratio were studied 3 monthly and bone mineral density (BMD) by DXA on 6-12 monthly basis. RESULTS: Fracture rate of the patients significantly decreased after treatment (1.2+/-1.5 vs. 0.16+/-0.32 per year, P<0.05). Treatment improved bone density in each individual case. Z-scores of lumbar DXA (L2-L4) significantly increased during treatment (-4.60+/-1.30 vs - 2.47+/-1.52, P< 0.05). Urinary pyrilinks-D decreased with treatment (90.8+/-136.3 vs. 35.1+/-29.9, P< 0.05). Serum Ca, P, ALP, OC and urinary Ca/Cr did not change significantly during treatment. CONCLUSION: We conclude that alendronate is effective, safe and practical alternative to intravenous bisphosphonates in treatment of children with OI.en_US
dc.description.affiliationMarmara University School of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey.en_US
dc.identifier.citationAkcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatrics. 2008 Feb; 45(2): 105-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/8720
dc.language.isoengen_US
dc.source.urihttps://indianpediatrics.neten_US
dc.subject.meshAdolescenten_US
dc.subject.meshBone Densityen_US
dc.subject.meshBone Density Conservation Agents --therapeutic useen_US
dc.subject.meshCalcium --therapeutic useen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDiphosphonates --administration & dosageen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshFractures, Bone --epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMaleen_US
dc.subject.meshOsteogenesis Imperfecta --drug therapyen_US
dc.subject.meshPrevalenceen_US
dc.subject.meshSeverity of Illness Indexen_US
dc.subject.meshVitamin D --therapeutic useen_US
dc.titleAlendronate treatment in children with osteogenesis imperfecta.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Pediatrics